Skip to main content
OpenTrials
Completed

NCT Number: NCT00184652

Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Novo Nordisk Investigational Site, København Ø, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ESRD patients

Exclusion criteria

  • Diabetes Mellitus
  • Severe and Malignant diseases
  • Patients in Intensive Care Units

Treatment and study plan

Somatropin

Drug

Primary outcomes

  1. Change in surrogate markers of nutrition

    Time frame: After 6 months treatment

Secondary outcomes

  1. Quality of Life

  2. Other markers of nutrition

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

The Effect of Norditropin® on Nutritional Status in Adult Patients in Chronic Haemodialysis

Important dates

Study start
2003
Primary completion
2005
Study completion
2005
First posted
Sep 16, 2005
Registry last updated
Jan 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.